Here are a few brief analogies for Bluejay Diagnostics:

• Like a smaller, focused **Abbott Laboratories** for specialized diagnostic tests.
• A startup developing innovative diagnostic platforms, similar to a mini-**Roche Diagnostics**.

• Symphony platform: A technology platform comprising an immuno-analyzer and a cartridge library, designed for blood processing, biomarker isolation, and immunoassay preparation.
• ALLEREYE diagnostic test: A point-of-care (POC) device used for the diagnosis of allergic conjunctivitis.
• Diagnostic Biomarkers: Specific markers, such as hsTNT/I and NT-proBNP, developed for the detection of diseases like myocardial injury and cardiac heart failure.

Based on the provided background information, the specific names of Bluejay Diagnostics' major customers are not identified.

However, given that Bluejay Diagnostics, Inc. develops and markets diagnostic products and platforms (such as the Symphony platform, ALLEREYE diagnostic test, and various biomarkers) for triage, diagnosis, and monitoring of disease progression, the company sells primarily to other companies and healthcare institutions (B2B). Its customer base would typically include:

• Hospitals and Healthcare Systems: For use in their diagnostic laboratories, emergency departments, and other clinical settings to aid in patient diagnosis and monitoring.
• Clinics and Physician Offices: Especially for point-of-care (POC) diagnostic devices like the ALLEREYE test, enabling rapid, in-office testing and diagnosis.
• Reference Laboratories: Institutions that perform specialized diagnostic testing services for a broad range of healthcare providers, utilizing advanced platforms and biomarker detection.

• Toray Industries, Inc. (TYO: 3402)

Neil Dey, President, Chief Executive Officer, and Principal Financial and Accounting Officer

Mr. Dey co-founded Bluejay Diagnostics in 2015. Before that, he co-founded Lana Management & Business Research International (LMBRI) in 2007, a management consulting company that specialized in the launch and marketing of medical products across the US, Japan, and EU. During his eight years at LMBRI, he consulted with companies such as Toray Industries, Hitachi Chemicals, and Fuji Chemicals. Prior executive positions include Vice President of Business Development and Market for Definines, AG (acquired by AstraZeneca) from 2005 to 2007. From 2001 to 2005, he was Head of Business Development, Western US, at IMPATH, Inc., where he was involved in introducing Her2neu Diagnostics. He also served as Chief Business Officer at Genmethrax, Inc., and held management roles in technology licensing at Thomas Jefferson Medical University and Ciba Geigy (Novartis). As of April 2, 2024, Mr. Dey also assumed the responsibilities of principal financial and accounting officer for Bluejay Diagnostics.

Kevin Vance, CCO

Les DeLuca, VP of Operations

Diane Palermo, Quality Assurance Manager

Amit K. Roy, Principal Scientist

The clear emerging threat for Bluejay Diagnostics (BJDX) is the rapid advancement and adoption of next-generation diagnostic technologies, such as CRISPR-based diagnostics, highly sensitive microfluidic systems, and non-invasive biosensors. These emerging technologies offer the potential for significantly superior speed, accuracy, multiplexing capabilities, and cost-effectiveness, which could render traditional fluorescence immunoassay platforms like BJDX's Symphony and its protein detection chips less competitive or potentially obsolete before they achieve widespread market penetration.

Bluejay Diagnostics (BJDX) develops and markets several diagnostic products and biomarkers. The addressable markets for these products are as follows:

ALLEREYE Diagnostic Test (for Allergic Conjunctivitis)

• The global allergic conjunctivitis market was valued at USD 3.37 billion in 2025 and is projected to reach USD 5.58 billion by 2034.
• North America represented the largest share of this market, valued at USD 1.65 billion in 2025 and USD 1.74 billion in 2026. The U.S. market alone is projected to reach USD 1.64 billion by 2026.
• More broadly, the global conjunctivitis market, which includes allergic, bacterial, and viral forms, was valued at USD 4.8 billion in 2023 and is expected to grow to USD 7.2 billion by 2033. Allergic conjunctivitis accounted for the largest share within this market in 2023.
• The allergic conjunctivitis segment of the conjunctivitis treatment market is expected to demonstrate the fastest growth rate, at 21.7% from 2025 to 2032.
• The global allergy point-of-care testing market, which includes devices like ALLEREYE, is forecasted to reach USD 1.6 billion in 2026 and expand to USD 4.2 billion by 2036.

Biomarkers for Myocardial Injury (hsTNT/I - high-sensitivity Troponin I)

• The global high-sensitivity Troponin I testing market size was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.8 billion by 2033.
• North America currently holds the largest share, over 38%, of the global High-Sensitivity Troponin I Testing market.
• The global cardiac troponin market size, which includes Troponin I, is estimated at USD 4.30 billion in 2025 and is predicted to increase to approximately USD 11.44 billion by 2035.
• Troponin I specifically dominated the cardiac troponin market in 2023 with a 58.2% market share.
• The broader global heart attack diagnostics market, which includes tests for myocardial injury, was valued at USD 11.18 billion in 2023 and is projected to reach around USD 25.05 billion by 2033. Blood tests, including high-sensitivity troponin, accounted for 41.02% of global revenue in 2025 within this market.

Biomarkers for Cardiac Heart Failure (NT-proBNP)

• The global NT-proBNP Test Kit market size is expected to grow from USD 1.2 billion in 2023 to a projected USD 2.5 billion by 2032.
• North America holds the largest share, approximately 45%, of the global BNP and NT-proBNP testing market.
• The global BNP and NT-proBNP market was valued at USD 1.92 billion in 2024 and is projected to reach USD 2.91 billion by 2030.
• The global BNP & NT-proBNP diagnostics market grew from USD 1.36 billion in 2025 to USD 1.57 billion in 2026 and is projected to reach USD 3.62 billion by 2032.
• The global market for BNP and NT-proBNP was valued at USD 1.1 billion in 2021 and is projected to reach USD 3.4 billion by 2031.
• The heart failure point-of-care (POC) and low-oxygen concentration (LOC) devices market, relevant to diagnostic platforms, was valued at approximately USD 91.7 million in 2023 and is estimated to grow at a 16.4% CAGR from 2024 to 2032. The U.S. heart failure POC and LOC devices market is also anticipated to grow at a 16% CAGR.

For Bluejay Diagnostics (NASDAQ: BJDX), expected drivers of future revenue growth over the next 2-3 years primarily revolve around the successful development, regulatory approval, and commercialization of its core diagnostic platform and associated tests.

1. Commercialization of the Symphony Platform and its Lead IL-6 Sepsis Test: The primary driver of future revenue growth is the successful regulatory clearance and subsequent market introduction of the Symphony platform, beginning with its lead product candidate, an Interleukin-6 (IL-6) test for sepsis risk assessment and critical care decision-making. Bluejay Diagnostics is actively advancing its SYMON™ II clinical study to generate data to support its regulatory strategy for this test. Once approved, the Symphony System, designed as a rapid, near-patient testing solution, is expected to be a key revenue generator in hospital and long-term acute care settings.

2. Scaling Manufacturing and Establishing a Robust Supply Chain: To support the commercialization efforts, Bluejay Diagnostics is focused on scaling up its manufacturing capabilities and strengthening its supply chain. The company has expanded its strategic partnership with SanyoSeiko Co., Ltd. for end-to-end support, including manufacturing redevelopment for analyzers and cartridges, raw material sourcing, and quality control. This readiness in production capacity and supply chain robustness is crucial for meeting anticipated market demand and enabling revenue generation from product sales.

3. Expansion of the Symphony Cartridge Library with New Biomarkers: Beyond the initial IL-6 test for sepsis, Bluejay Diagnostics' Symphony platform is designed to accommodate a library of diagnostic cartridges. The company is developing additional biomarkers for the detection of other diseases, such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. The successful development and regulatory approval of these additional tests would diversify Bluejay's product offerings and create new revenue streams by expanding the platform's diagnostic utility into broader critical care areas.

Share Issuance

• Bluejay Diagnostics raised $3.5 million through a public offering in January 2024.
• The company raised an additional $8.57 million through a public offering in June 2024.
• On October 10, 2025, Bluejay Diagnostics completed a private placement, generating $4.5 million in gross proceeds from the sale of common stock and warrants, with proceeds intended to fund FDA approval efforts, clinical studies, and research and development.

Inbound Investments

• Bluejay Diagnostics secured $1 million in Bridge Note Financing in May 2024.
• The company completed a $3.8 million warrant-inducement financing in April 2025.
• A $4.5 million private placement (PIPE financing) closed in October 2025.

Capital Expenditures

• Capital expenditures for the last 12 months were reported as -$1,352, indicating minimal new investment or net sales of property, plant, and equipment.
• Proceeds from the October 2025 private placement are intended to fund FDA approval efforts, clinical studies, research and development activities, and general working capital needs.
• The company plans to transfer the manufacturing of Symphony cartridges to an in-house facility for redevelopment, followed by a transfer to an FDA-registered Contract Manufacturing Organization. This indicates a primary focus on manufacturing scale-up and operational readiness in capital allocation.